secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-004155
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools CCO Jeremy Davis to depart Feb 1, 2025; severance details disclosed
--------------------------------------------------------------------------------

- Jeremy Davis will step down as Chief Commercial Officer effective February 1, 2025, by mutual agreement.
- Severance includes 12 months' base salary continuation of $441,000 plus 2024 bonus of $169,785.
- Pro-rated target bonus of $21,264.65 and COBRA premium payments through Feb 2026 or earlier.
- Outstanding unvested equity awards will receive 100% vesting acceleration, with performance-based awards at target.
- Severance agreement to be filed with Q1 2025 10-Q; no replacement yet announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025004155/0000950170-25-004155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025004155/lab-20250103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer